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Research Article 
INTRODUCTION 
Leukaemia is a malignant neoplasm of hematopoietic 
cells. Aberrant gene expression related to cellular dif-
ferentiation, and proliferation of hematopoietic cell con-
tributes to malignant transformation of cells. A better 
understanding of differential gene expression (DGE) in 
leukemia should provide diagnostic biomarkers, and 
therapeutic targets for therapy of this disease. Differen-
tial gene expression analysis refers to the analysis, and 
interpretation of differences in the abundance of gene 
transcripts within a transcriptome (Conesa et al., 2016). 
DGE is important to understand the biological differ-
ences between healthy and diseased states (Rodriguez 
et al., 2017). Identification and characterization of po-
tent diagnostic biomarkers, and therapeutic targets rely 
heavily on traditional in vitro screens which require ex-
tensive resources and time. Integration of in silico 
screens prior to experimental validation can improve 
the efficiency and potency of biomarkers as well as 
reduce the cost and time of biomarker discovery. Con-
sidering the need, present work was undertaken to 
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A biomarker can be measured, used to diagnose or classify disease, and measure progress as well as the therapeutic response 
of the disease. Early diagnosis and selection of appropriate treatment can be critical for the successful treatment of diseases. 
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ysis and co-regulated expression analysis were used for in silico identification and characterise a potent biomarker for leukemia. 
On the basis of in silico screening, the present study proposed seven protein-coding (CD38, TSC22D3, TNFRSF25, AGL, 
LARGE1, ARHGAP32, and PARM1) genes for the diagnosis of leukemia. The study also proposed a novel three-step lineage-
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identify biomarkers for different classes of leukemia. In 
the present work, the combination of differential gene 
expression analysis and co-regulated expression analy-
sis were used for in silico identification of potent bi-
omarkers for leukemia. 
MATERIALS AND METHODS 
Microarray datasets selection  
In order to find proper gene expression profiles in mi-
croarray datasets, a systematic search was performed 
in Gene Expression Omnibus (GEO) database (https://
www.ncbi.nlm.nih.gov/geo/) using the keywords “AML” 
and “Serum”, “CML” and “Serum”, “Acute Lympho-
blastic Leukemia” and “Serum”. These broad searches 
yielded a large number of gene expression data sets. 
The search was first narrowed down to a few potential 
data sets using various filters such as “Homo sapiens” 
and “Expression Profile by Array” in the GEO database. 
Finally, by detailed study of data sets four normalized 
data sets were selected. The flowchart of the dataset 
selection procedure, filter features of data sets, and 
information of datasets are shown in Fig. 1. 
Selection and combination of top differentially  
expressed gene (DEG) 
Differentially expressed genes of four different types of 
leukemia were analyzed using the online tool GEO2. 
GEO2R is an interactive tool that enables the analysis 
of GEO datasets. It uses a web-based program, that 
employs the Bioconductor packages, and limma R 
(Gentleman et al., 2004; Smyth, 2004). A Venn diagram 
was prepared for the combination of four different sets 
of four different types of leukemia. InteractiVeen 
(Heberle et al., 2015) online tool was used to combine 
all data set to find out overlapping and non-overlapping 
differentially expressed gene. In order to find the best 
common biomarker for all classes of leukemia, and to 
prevent missing critical genes, it was decided to select 
differentially expressed gene overlapped between at 
least two data sets.                           
Area under curve (AUC) analysis 
The expression values of selected overlapping differen-
tially expressed genes were extracted in the form of a 
soft file, and imported to GraphPad Prism software. 
Receiver-operating characteristic (ROC) curves, and 
area under the ROC curve (AUC) were used to assess 
the detection ability of each differentially expressed 
gene in the diagnosis of different classes of leukaemia 
from the control group based on the sensitivity and 
specificity of each differentially expressed gene. The 
higher the AUC, better the model would be. 
Hierarchical clustering analysis 
Individual expression values of significantly up/down-
regulated differentially expressed genes in leukaemia 
were logarithm transformed, and were used as input 
values for the hierarchical clustering algorithm. The 
following criteria were applied: the distance chose 
“Pearson Correlation”, and the linkage selected 
“average”. The result is demonstrated as a Heatmap. 
Heatmapper webserver was used for the preparation of 
the heatmap. 
RESULTS 
Microarray dataset selection 
 The selected microarray dataset and their features for 
different classes of leukemia are shown in Table 1. The 
volcano plot and mean difference plot are presented 
from Fig. 2- 9 for each selected microarray dataset. A 
volcano plot displayed statistical significance (-log10 P 
value) versus magnitude of change (log2 fold chain) of 
differentially expressed gene and the mean difference 
plot displays log2 fold chain versus average log2 ex-
pression value. Highlighted genes were significantly 
Fig. 1. Microarray dataset selection procedure for GO2R 
Analysis, and identification of top 250 differentially ex-
pressed genes for four classes of leukemia. 
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differentially expressed at a default adjusted p-value 
cut-off of 0.05 (red= upregulated and blue= downregu-
lated).  
Selection and combination of top differentially ex-
pressed gene (DEG) 
After GEO2R analysis, 164 genes for AML, 202 genes 
for ALL, 146 genes for CLL and 194 for CML showed 
significantly up/downregulation. After integration of the 
results with the help of Venn diagram, one gene was 
common in AML, ALL and CLL, six genes were com-
mon in Acute leukemias (ALL and AML), five genes 
were common in Chronic leukemias (CML and CLL), 
four genes were common in Myeloid leukemias (AML 
and CML) and six genes were common in Lymphoid 
leukemias (ALL and CLL). Details of common genes 
are shown in Fig. 10 and Table 2.  
Area under curve (AUC) analysis 
On the basis of the lowest adjusted p value of common 
differentially expressed seven genes from different 
groups (CD38, TSC22D3, TNFRSF25, AGL, LARGE1, 
ARHGHP32, and PARM1) were selected for further 
analysis. After extraction of expression values for all 
seven DEGs, in order to find the reliable marker in dis-
criminating leukemia from healthy controls, AUC analy-
sis was performed and ROC curves for seven DEG 
were prepared. ROC curve AUC values of seven DEG 
for different groups are shown in Table 3. 
Hierarchical clustering analysis and co-expression 
correlation 
Fig. 11-14 demonstrates hierarchically clustered 
Heatmaps built up using the expression values of 
DEGs for four classes of leukaemia. Four differentially 
expressed genes AGL, CD38, TNFRSF25, TSC22D3 
are shown in the Heatmap of AML. AGL and CD38 
showed downregulation and TNFRSF25, TSC22D3 
showed upregulation in AML patients. Similarly, four 
differentially expressed genes LARGE1, TNFRSF25, 
CD38, TSC22D3 are shown in the Heatmap of ALL. 
LARGE1, TNFRSF25, and TSC22D3 showed co-
expression and upregulation in ALL patients and CD38 
showed down-regulation. Three differentially expressed 
genes AGL, ARHGAP32, and PARM1 are shown in the 
Heatmap of CML. ARHGAP32 and PARM1 showed 
downregulation and AGL showed upregulation in CML 
patients. Four differentially expressed genes LARGE1, 
ARHGAP32, CD38, and PARM1 are shown in the 
Heatmap of CLL. All four genes showed similar co-
expression patterns and down-regulated in CLL. 
DISCUSSION  
In recent years, there has been an increased emphasis 
on personalized and targeted therapy for leukemia pa-
tients. Therefore, it is important to explore the mecha-
nism for the development of novel therapeutic strate-
gies.  Recently, differential gene expression profiling 
analysis has been widely used to reveal abnormal 
gene expression patterns related to leukemia, to identi-
fying novel diagnostic and therapeutic targets. In the 
present study, differential gene expression analysis 
and co-regulated gene expression analysis were used 
to identify some novel diagnostic and therapeutic  
targets.  
By using in silico methods, the present study proposed 
seven new protein-coding genes for the diagnosis of 
S.N. GEO accession number Leukemia Platform Samples Authors 
01 GSE90062 AML GPL15207 Control=03, AML=03 Li et al., 2017 
02 GSE42221 ALL GPL96 Control=04, ALL=07 Harder et al., 2013 
03 GSE97562 CML GPL6244 Control=20, CML=20 Aviles et al., 2017 
04 GSE26725 CLL GPL570 Control=05, CLL=12 Vargova et al., 2011 
Table 1. Selected microarray dataset for GO2R analysis, and identification of top 250 differentially expressed genes for 
four classes of leukemia. 
Leukemia 
Number of common 
protein coding DEG 
Symbol of common protein coding DEG 
AML, ALL, CLL 1 CD38 
ALL, AML 6 GJA1, SH3BP5, SLC1A4, TSC22D3, PHGDH, TNFRSF25 
CLL, CML 5 ARHGAP32, FRY, CAMK1D PIK3R6, PARM1 
AML, CML 4 AGL, LHFP, CHCHD7, TMEM154 
ALL, CLL 6 ANP32E, LARGE1, IGLC1, CYAT1, SMAGP, ITM2C 
Table 2. Details of Common Differentially Expressed Gene (DEG). 
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Leukemia type Gene Area Stander error p value 
AML CD38 0.8762 0.0524 0.0001 
AML TSC22D3 1.0000 0.0000 0.0495 
AML TNFRSF25 1.0000 0.0000 0.0495 
AML AGL 1.0000 0.0000 0.0490 
ALL CD38 1.0000 0.0000 0.0082 
ALL TSC22D3 1.0000 0.0000 0.0082 
ALL TNFRSF25 1.0000 0.0000 0.0495 
ALL LARGE1 1.0000 0.0082 0.0082 
CML    ARHGAP32 0.8800 0.0590 0.0001 
CML PARM1 0.8825 0.0549 0.0001 
CML AGL 0.08513 0.0598 0.0001 
CLL CD38 1.0000 0.0000 0.0016 
CLL ARHGAP32 0.9236 0.07371 0.0004 
CLL PARM1 1.0000 0.0000 0.0016 
CLL LARGE1 1.0000 0.0000 0.0016 
Table 3. AUC analysis for seven DEGs. 
Fig. 2. Volcano plot of AML.            Fig. 3. Mean difference plot of AML  
Fig. 5. Mean difference plot of ALL.    Fig. 4. Volcano plot of ALL.                 
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leukemia. To identify protein-coding genes as bi-
omarkers, four GEO microarray datasets containing the 
expression profiles from the serum of leukemia patients 
and healthy controls were chosen for differential ex-
pression analysis. Four GEO microarray dataset 
GSE90062, GSE42221, GSE97562, and GSE26725 
comprises gene expression data for AML, ALL, CML, 
and CLL respectively. The gene expression profile data 
were downloaded, and analyzed using the GEO2R. 
Top 250 genes were selected from each microarray 
data sets. Common genes between different classes of 
leukemia were captured out with the help of the Venn 
diagram. On the basis of the lowest adjusted p values, 
seven genes were selected from different groups of 
leukemia. The expression values for all these differen-
tially expressed genes were extracted and normalized. 
Using Area Under ROC curve Analysis (AUC), the most 
powerful DEGs in discriminating the leukemia patient 
from a healthy control were picked out. In the present 
study, a total seven genes showed AUC > 0.800 and 
considered for further analysis. The co-expression pat-
tern of seven identified genes was analyzed by hierar-
chically clustered Heatmaps built up using the expres-
sion values of DEGs. The present study also proposed 
a three-step lineage-specific model for the diagnosis of 
leukemia. In the three-step diagnosis model, the first 
group of biomarkers with an association of clinical and 
hematological parameters diagnose leukemia, the sec-
ond group of biomarkers diagnoses acute and chronic 
form of leukemia and the third group of biomarkers 
identifies whether it belongs to myeloid lineage or lym-
phoid lineage.  
Tripathi and Pandya (2016) carried out a similar study 
when they studied differential analysis of gene expres-
sion for acute myeloid leukemia. They analyzed the 
transcriptional profiling of human T-cell involved in the 
AML disease and reported CD4, NA, ADTRP genes as 
a diagnostic and therapeutic biomarker. Tang et al. 
(2019) reported the five key genes: ACTR2, ARPC3, 
ARPC5, CTTN, and APP may be implicated in tumor 
progression and could potentially represent promising 
prognostic biomarkers and therapeutic targets for AML 
Fig. 6. Volcano plot of CLL.           Fig. 7. Mean difference plot of CLL.  
Fig. 8. Volcano plot of CML.            Fig. 9. Mean difference plot of CML.   
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patients. Wei Fu et al. (2020) reported abnormal ex-
pression of CYBB, CYFIP2, SERPINE1, and ITGAM 
based on high-throughput data analysis. Sanchez and 
Mackenzie (2020) reported integrative network analysis 
of differentially methylated and expressed genes for 
biomarker identification in leukemia. There are many 
studies that have been reported (Prada et al., 2017, 
Jiang et al., 2016, Sweet et al., 2013) for the identifica-
tion and characterization of biomarkers for individual 
classes of leukemia, but the present study was carried 
out for the comparative analysis of biomarker profiling 
of major classes (AML, ALL, CML, and CLL) of leuke-
mia.   
In the present study, the CD38 gene is a common dif-
ferentially expressed gene in AML, ALL, and CLL. AUC 
analysis of CD38 shows, it is a good classifier marker 
for ALL and CLL. Jiang et al., (2016) also reported 
CD38 expression in HSCs, Leukemic stem cells, and B
-ALL.  
There are six differentially expressed genes that are 
commonly involved in acute leukemias. Out of these 
TSC22D3 and TNFRSF25 were selected on the basis 
of the lowest p-value. AUC analysis of TNFRSF25 
shows that, it is a good classifier marker for acute leu-
kemia. Miller et al., (2007) reported TSC22D3 (TSC22 
domain family member) was highly induced in all the 
leukemic cells tested, regardless of apoptotic sensitivity 
Fig. 10. Venn diagram of common differentially expressed 
gene (DEG). 
Fig. 11. Heatmap for AML.                        Fig. 12 Heatmap for ALL.  
Fig. 13. Heatmap for CML.                         Fig. 14. Heatmap for CLL.  
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or resistance. Yang et al. (2019) reported the role of 
upregulated TSC22D3 and stress-induced glucocorti-
coid surge in therapy-induced anticancer immunosur-
veillance. Paul et al., (2008) studied that TNFRSF25 
(Tumor necrosis factor receptor superfamily member 
25) are hypermethylated in tumor tissue. TNFRSF25 
was significantly up-regulated in ECFCs (Endothelial 
colony-forming cells) from VTE (Venous thromboembo-
lism) patients. Through experiments of functional vali-
dation, they further demonstrated that the upregulation 
of TNFSF15–TNFRSF25 axis sustains reduced survival 
and proliferation of ECFCs in VTE patients, thus sug-
gesting that this molecular pathway, by impairing endo-
thelial repair, may contribute to VTE pathogenesis. 
Five genes were differentially expressed in chronic leu-
kemia. Out of these ARHGAP32 and PARM1 were se-
lected on the basis of the lowest p-value. AUC analysis 
of these two genes shows both are good classifier 
markers for CLL. A similar observation was reported by 
Vlaanderen et al. (2017), in which they reported 
ARHGAP32 as a pre-diagnostic blood transcriptome 
marker of chronic lymphocytic (CLL). Paulisally et al., 
(2014) identified PAMR1 (Peptidase domain-containing 
associated with muscle regeneration 1) as being fre-
quently suppressed in breast cancer tissues. They re-
ported that PAMR1 expression was reduced in all test-
ed breast cancer cell lines, while PAMR1 was ex-
pressed moderately in normal breast tissues and pri-
mary mammary epithelial cells. Li (2020), reported the 
PARM1 key target gene for mir-382-5P regulating ovar-
ian cancer. 
In the present study, four common genes are differen-
tially expressed in myeloid leukemia and six genes in 
lymphoid leukemia. AUC analysis of these genes 
showed AGL and TMEM154 is good classifier marker 
for AML and LARG1 is good classifier marker for both 
lymphoid leukemia.  In the present study, the overall 
expression of AML (Fig. 2 and 3 Volcano plot and 
mean difference plot) showed that more differentially 
expressed genes were overexpressed. 164 genes were 
exclusively expressed in AML.  Heatmap of CD38 
showed that it is an overexpressed gene in AML and it 
is downregulated in ALL and CLL. In addition to CD38, 
AGL and TMEM154 are good classifier marker for 
AML. Crushell et al., (2010) confirmed that AGL en-
codes the glycogen debrancher enzyme, which is in-
volved in glycogen degradation, and it was significantly 
altered, carbohydrate metabolic process in response to 
glucocorticoid stimulus. Guin et al., (2016) confirmed 
that AGL also involved in the induction of hyaluronic 
acid synthesis and further regulate tumor growth in 
bladder cancer. Holroyde et al., (1984) showed that 
diverse abnormalities of the carbohydrate metabolic 
process often occurred in cancer cachexia, such as 
colorectal cancer. In addition, aerobic glycolysis was 
ensured to be a metabolic adaptation that promotes the 
proliferation of colorectal cancer cells (Straus et al., 
2013). 
In the present study, the overall expression of ALL (Fig. 
4 and 5 Volcano plot and mean difference plot) showed 
that more differentially expressed genes were under-
expressed. 202 genes were exclusively expressed in 
ALL. In contrast with AML, the heatmap of CD38 
showed that CD38 was an under-expressed gene in 
ALL. AUC analysis showed ARHGAP32, PARM1, and 
LARGE1 can be used as biomarkers for ALL. The over-
all expression of CLL and CML (Fig. 6- 9 Volcano plot 
and mean difference plot) showed that more differen-
tially expressed genes were overexpressed. 146 genes 
were exclusively expressed in CLL and 194 genes 
were exclusively expressed in CML.  
Conclusion 
Using multiple bioinformatics tools and on the basis of 
the lowest adjusted p value and AUC analysis present 
study proposed seven differentially expressed genes 
(CD38, TSC22D3, TNFRSF25, AGL, LARGE1, 
ARHGAP32, and PARM1) as biomarkers for leukemia. 
In conclusion, this study supports the accuracy of some 
formerly proposed biomarkers (CD38, and AGL) for 
leukemia, and also has suggested new candidate bi-
omarkers (TSC22D3, TNFRSF25, LARGE1, 
ARHGAP32, and PARM1) which can be used as diag-
nostic or prognostic means or as therapeutic targets.  
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